<DOC>
	<DOCNO>NCT00758524</DOCNO>
	<brief_summary>This study proof-of-efficacy , dose find study LCI699 patient mild-to-moderate uncomplicated essential hypertension order ass BP lower effect , safety tolerability LCI699 compare placebo eplerenone .</brief_summary>
	<brief_title>A Multi-center , Randomized , Double-blind , Placebo Active Controlled , Parallel Group , Dose Finding Study Evaluate Efficacy Safety LCI699 , New Experimental Antihypertensive Drug , Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Males nonfertile female 1875 year inclusive Patients mildtomoderate uncomplicated essential hypertension All woman child bear potential . Female patient hormone replacement therapy . Severe hypertension History evidence secondary form hypertension Known moderate malignant retinopathy History angina pectoris , myocardial infarction , coronary bypass surgery , ischemic heart disease , surgical percutaneous arterial intervention kind ( coronary , carotid peripheral vessel ) , stroke , transient ischemic attack ( TIA ) , carotid artery stenosis , aortic aneurysm peripheral arterial disease . Type 1 type 2 diabetes mellitus . Clinically significant valvular heart disease . Congestive heart failure ( NYHA class IIIV ) . Cardiac electrical abnormality indicate significant risk safety patient participate study History malignancy organ system , treat untreated , within past 5 year . Liver disease cirrhosis chronic active hepatitis . Any surgical medical condition may significantly alter absorption , distribution , metabolism excretion drug substance Any surgical medical condition , identify protocol opinion investigator monitor , place patient high risk his/her participation study , likely prevent patient comply requirement study complete trial period . Patients unwilling able discontinue safely use current antihypertensive medication study period Any contraindication history hypersensitivity study drug drug similar chemical structure . Chronic oral parenteral corticosteroid treatment Treatment potassium supplement potassium spar diuretic Treatment potent CYP3A4 inhibitor study period Use investigational drug Visit 1 , within 30 day 5 halflives Visit 1 , whichever long , unless local health authority guideline mandate longer period . Serum potassium &gt; 5.2 mEq/L &lt; 3.5 mEq/L Visit 1 . Serum sodium &lt; 132 mEq/L Visit 1 . ALT AST &gt; 2 time upper limit normal range ( ULN ) Visit 1 . Bilirubin ( total ) &gt; 1.5 x ULN Visit 1 . MDRD eGFR &lt; 60 ml/min/1.73 m2 Visit 1 . Other clinically significant laboratory abnormality , confirm repeat measurement , Visit 1 . History active substance abuse ( include alcohol ) Patients nightshift employment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>phase 2 study</keyword>
	<keyword>antihypertensive agent</keyword>
</DOC>